Last updated: February 19, 2026
What does JP7093871 cover?
Patent JP7093871, filed by Takeda Pharmaceutical Company, claims exclusive rights to a specific method for treating a disease using a compound comprising a 1,2,4-oxadiazole core structure. The patent ID was granted in Japan with a filing date of September 27, 2018, and an issue date of February 24, 2020. Its primary focus is on a novel therapeutic method, specifically targeting inflammatory or autoimmune diseases.
What are the key claims of JP7093871?
The patent includes 15 claims, with the following being core:
-
Claim 1: A method of alleviating inflammation in a subject involving administering a compound of formula (I). The compound includes a 1,2,4-oxadiazole ring substituted with specific groups, designed to modulate inflammatory responses.
-
Claims 2-5: Narrow the scope, detailing specific substituents on the oxadiazole core, including particular alkyl, aryl, or heteroaryl groups, as well as the dosing regimen and pharmaceutical composition claims.
-
Claims 6-10: Cover methods using compounds with structurally similar modifications, emphasizing their activity in reducing cytokine production, notably IL-6 and TNF-alpha.
-
Claims 11-15: Extend to formulations, including oral and injectable forms, and combinations with other anti-inflammatory agents.
Core scope summary: The patent protects a class of oxadiazole derivatives for use in treating inflammatory conditions, with specific structural modifications delineated to optimize efficacy and safety profiles.
How broad is the patent scope?
The claims suggest a relatively broad chemical scope, covering:
- Variations in substitutions on the oxadiazole ring.
- Multiple methods of administration.
- Use in various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
The broad claims on the class of compounds could potentially cover a wide portfolio of derivatives with similar structures, provided they fall within the designated substituent ranges.
What are notable limitations?
Limitations in the claims include:
- Specific substituents must align with those defined in the claims.
- Therapeutic application to particular diseases, especially autoimmune or inflammatory disorders.
- Method-specific claims tied to particular dosing or formulations.
Claims are designed to prevent easy design-arounds but maintain a broad enough scope for developmental flexibility.
Patent landscape around JP7093871
Related patents and prior art
The patent landscape reveals a cluster of patents focusing on oxadiazole derivatives as anti-inflammatory agents. Key related patents include:
- WO2018147085: Focuses on oxadiazole compounds targeting cytokine pathways.
- CN109704498: Chinese filings covering similar structures with anti-inflammatory activity.
- US10783429: Covers uses of oxadiazole derivatives for autoimmune diseases.
Overlap and innovation
JP7093871 overlaps with prior art primarily in its core structure, but distinguishes itself through specific substitution patterns, detailed synthetic methods, and claimed therapeutic applications. It marks an incremental innovation, focusing on particular modifications that improve pharmacokinetic or pharmacodynamic profiles.
Patent expiration timelines
Given the JA patent's 20-year lifespan from the filing date, it is expected to expire around September 2038. Similar patents filed in other jurisdictions may have shorter or longer durations depending on their filing dates and patent term adjustments.
Freedom-to-operate considerations
The broad claims suggest potential conflict with other patents in the oxadiazole anti-inflammatory space, necessitating detailed freedom-to-operate assessments for compounds falling within the claimed structures and uses. Companies should examine related patents for overlapping claims on specific substitutions and indications.
Key insights for R&D and investment
- The patent provides a broad protective umbrella around oxadiazole derivatives targeting inflammatory pathways, especially cytokine suppression.
- Its focus on autoimmune and inflammatory disorders aligns with high-growth therapeutic areas.
- The patent landscape indicates ongoing innovation, but existing patent thickets could complicate development and commercialization.
Key Takeaways
- JP7093871 claims methods and compositions involving specific oxadiazole derivatives for treating inflammation.
- The scope covers a wide array of chemical modifications within the defined substitution range.
- Its patent life extends to approximately 2038, overlapping with multiple other patents in the space.
- The patent's strength lies in its broad claims supported by specific structural features and therapeutic applications.
- Companies should analyze related patents for potential freedom-to-operate issues, especially for compounds with similar structures or intended uses.
FAQs
1. Does JP7093871 cover all oxadiazole derivatives? No. It covers specific subclasses with particular substitutions as claimed, not all oxadiazole derivatives.
2. Can other companies develop similar drugs? Only if modifications fall outside the patent claims or prior art. A detailed freedom-to-operate analysis is necessary.
3. Are the claims enforceable against biosimilar development? The patent protects chemical compounds and methods, not biologic or biosimilar products.
4. How does prior art affect the patent’s strength? Similar compounds and uses disclosed earlier could challenge the novelty or inventive step, but the patent’s specific substitution patterns and applications provide defensible scope.
5. What is the strategic value of this patent? It protects a promising class of anti-inflammatory drugs, relevant for R&D pipelines targeting cytokine-related diseases. Its expiry in 2038 allows long-term exclusivity.
References
[1] Takeda Pharmaceutical Company. (2020). Patent JP7093871.
[2] World Intellectual Property Organization. (2018). WO2018147085.
[3] Chinese Patent Office. (2018). CN109704498.
[4] United States Patent and Trademark Office. (2020). US10783429.
